TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
Recruiting
- Conditions
- Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
- Registration Number
- NCT05729711
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Inclusion Criteria:<br><br> - The evaluable patients are those treated with Tezspire for the first time due to<br> Bronchial asthma (only the patients with severe or intractable bronchial asthma<br> which could not be controlled with the existing therapy)<br><br>Exclusion Criteria:<br><br>None
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of ADRs
- Secondary Outcome Measures
Name Time Method